Partner with Us to Discover Next Generation Breakthrough Drugs
GNS has R&D programs based on current Gemini Virtual Patients in multiple myeloma, solid tumors, neurodegenerative disorders, and immunology that are leading to the discovery and development of breakthrough therapeutic candidates. GNS contributes AI-discovered novel and validated drug targets as “a method for therapeutic intervention” across a variety of indications. These targets and corresponding biomarkers are causally linked to the clinical endpoints in each indication, and defined in a specific patient sub-population, offering a new level of mechanistic understanding of the therapeutic potential of each novel target.
GNS has partnered with leading biopharma companies to advance these “Virtual Patient” derived novel and validated drug targets, in addition to prioritizing candidate targets and therapeutics. Please contact us if you’d like to discuss drug discovery partnership opportunities.